AU2021316192A1 - Methods for the use of a PD-1 x CTLA-4 bispecific molecule - Google Patents

Methods for the use of a PD-1 x CTLA-4 bispecific molecule Download PDF

Info

Publication number
AU2021316192A1
AU2021316192A1 AU2021316192A AU2021316192A AU2021316192A1 AU 2021316192 A1 AU2021316192 A1 AU 2021316192A1 AU 2021316192 A AU2021316192 A AU 2021316192A AU 2021316192 A AU2021316192 A AU 2021316192A AU 2021316192 A1 AU2021316192 A1 AU 2021316192A1
Authority
AU
Australia
Prior art keywords
cancer
ctla
dose
bispecific molecule
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021316192A
Other languages
English (en)
Inventor
Alexey Yevgenyevich Berezhnoy
Ezio Bonvini
Sharad Sharma
Bradley JAMES SUMROW
Jon Marc Wigginton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrogenics Inc
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of AU2021316192A1 publication Critical patent/AU2021316192A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AU2021316192A 2020-07-27 2021-07-23 Methods for the use of a PD-1 x CTLA-4 bispecific molecule Pending AU2021316192A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063057054P 2020-07-27 2020-07-27
US63/057,054 2020-07-27
US202163177036P 2021-04-20 2021-04-20
US63/177,036 2021-04-20
US202163219066P 2021-07-07 2021-07-07
US63/219,066 2021-07-07
PCT/US2021/042901 WO2022026306A1 (en) 2020-07-27 2021-07-23 Methods for the use of a pd-1 x ctla-4 bispecific molecule

Publications (1)

Publication Number Publication Date
AU2021316192A1 true AU2021316192A1 (en) 2023-02-23

Family

ID=80036053

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021316192A Pending AU2021316192A1 (en) 2020-07-27 2021-07-23 Methods for the use of a PD-1 x CTLA-4 bispecific molecule

Country Status (13)

Country Link
US (1) US20230312756A1 (cg-RX-API-DMAC7.html)
EP (1) EP4188961A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023536086A (cg-RX-API-DMAC7.html)
KR (1) KR20230042038A (cg-RX-API-DMAC7.html)
CN (1) CN116134053A (cg-RX-API-DMAC7.html)
AU (1) AU2021316192A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001487A2 (cg-RX-API-DMAC7.html)
CA (1) CA3189926A1 (cg-RX-API-DMAC7.html)
IL (1) IL300166A (cg-RX-API-DMAC7.html)
MX (1) MX2023001111A (cg-RX-API-DMAC7.html)
TW (1) TW202220691A (cg-RX-API-DMAC7.html)
WO (1) WO2022026306A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202300822B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120648657A (zh) * 2024-03-08 2025-09-16 上海锦斯生物技术有限公司 一种修饰的溶瘤病毒及其组合物
WO2026021409A1 (zh) * 2024-07-22 2026-01-29 宜明昂科生物医药技术(上海)股份有限公司 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法
WO2026067794A1 (en) * 2024-09-30 2026-04-02 Shen Shi Pharmaceuticals (Shanghai) Co., Ltd. Trispecific antibodies and uses thereof
WO2026117666A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Bispecific antibodies for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
CN108367069B (zh) * 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
US20190241658A1 (en) * 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
IL321475A (en) * 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
CA3026151A1 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN106967172B (zh) * 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2019179421A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
US20210079094A1 (en) * 2019-03-29 2021-03-18 Xencor, Inc. Dosing of a bispecific antibody that binds pd1 and ctla4

Also Published As

Publication number Publication date
TW202220691A (zh) 2022-06-01
MX2023001111A (es) 2023-03-07
EP4188961A4 (en) 2024-08-07
ZA202300822B (en) 2023-08-30
KR20230042038A (ko) 2023-03-27
US20230312756A1 (en) 2023-10-05
EP4188961A1 (en) 2023-06-07
CA3189926A1 (en) 2022-02-03
BR112023001487A2 (pt) 2023-02-14
JP2023536086A (ja) 2023-08-23
CN116134053A (zh) 2023-05-16
IL300166A (en) 2023-03-01
WO2022026306A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
US20240084015A1 (en) Methods of using bispecific molecules having immunoreactivity with pd-1 and ctla-4
TWI788327B (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
TWI780057B (zh) 針對tim3之抗體及其用途
CN113301919B (zh) 激活免疫细胞的双特异性抗体
JP6449338B2 (ja) グルココルチコイド誘導腫瘍壊死因子受容体(gitr)に対する抗体およびその使用
US20230312756A1 (en) Methods for the use of a pd-1 x ctla-4 bispecific molecule
US20230056230A1 (en) Therapy for the Treatment of Cancer
WO2017087678A2 (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
TW201627322A (zh) 抗-dr5抗體和包括其dr5-結合結構域的分子
TW201627323A (zh) 包含dr5-結合結構域的多價分子
JP2021505637A (ja) 二重特異性cd16結合分子、及び疾患の治療におけるその使用
RU2805648C2 (ru) Биспецифические связывающие молекулы, способные связывать cd137 и опухолевые антигены, и варианты их применения
EA046873B1 (ru) Cd137-связывающие молекулы и варианты их применения
HK40113244A (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
NZ782254A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof